tiprankstipranks
Advertisement
Advertisement

Vanda Announces Resignation of Senior Legal Executive

Story Highlights
  • Vanda Pharmaceuticals announced the resignation of senior legal executive Timothy Williams.
  • His April 10, 2026 departure shifts legal leadership, affecting governance and oversight.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Vanda Announces Resignation of Senior Legal Executive

Meet Samuel – Your Personal Investing Prophet

Vanda ( (VNDA) ) has issued an update.

On March 29, 2026, Vanda Pharmaceuticals Inc. announced that Timothy Williams resigned from his role as Senior Vice President, General Counsel and Secretary. His resignation, effective April 10, 2026, marks a change in the company’s executive leadership team as he departs to pursue other endeavors, potentially prompting adjustments in Vanda’s legal and corporate governance functions.

The transition in a key legal and governance position may have implications for how Vanda manages regulatory, compliance and strategic corporate matters going forward. Stakeholders and industry observers are likely to watch how the company fills this senior role and maintains continuity in its legal oversight and corporate administration.

The most recent analyst rating on (VNDA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.

Spark’s Take on VNDA Stock

According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.

The score is held back primarily by weak financial performance—deepening losses, heavy cash burn, and equity erosion—despite low leverage. Offsetting this are strong technical momentum and a balanced but improving business outlook from the earnings call, including revenue growth guidance and recent approvals, though near-term cash burn and execution risks remain significant.

To see Spark’s full report on VNDA stock, click here.

More about Vanda

Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative therapies, operating within the pharmaceutical and life sciences industry. The company focuses on prescription medicines, targeting unmet medical needs and specialized patient populations in the U.S. and other markets.

Average Trading Volume: 2,587,083

Technical Sentiment Signal: Buy

Current Market Cap: $417.9M

See more insights into VNDA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1